QbAccess Offers Grants to Underserved Clinics and Organizations to Provide FDA-Cleared Objective Tests to Critical Populations

Qbtech, the global leader in objective ADHD testing, today announced the launch of its new grant program, QbAccess. Created to make ADHD testing and care more accessible to underserved populations, the program provides non-profit healthcare organizations with access to Qbtech’s FDA-cleared objective ADHD testing devices at a reduced rate.

Non-profit clinics serve an estimated 40 million people each year, with 90% of the patients living at or below 200% of the federal poverty level. The goal of QbAccess is to help reduce health disparities by ensuring low-income populations have access to high-quality ADHD evaluation services to improve clinical outcomes. Through the program, non-profit healthcare organizations, including Federally Qualified Healthcare Centers (FQHCs) and Tribal Clinics, can apply for grant funding to receive access to Qbtech’s objective ADHD testing technology.

“The launch of QbAccess is another milestone for Qbtech and aligns with our mission to improve the lives of those with ADHD,” said Qbtech CEO Carl Reuterskiöld. “With this program, we hope to reach critical populations in the U.S. where better mental and behavioral healthcare is needed, especially for those suffering from undiagnosed or untreated ADHD. Coupled with our team’s advocacy work to maintain and improve remote ADHD care, we believe we can truly make an impactful difference.”

The concept for QbAccess stemmed from Qbtech’s Company Days 2023, where employees were given the opportunity to present ideas that would enhance innovation or create additional pathways to improve the lives of ADHD patients. After presentations to company leadership and the Board of Directors, QbAccess was selected for its alignment with Qbtech’s company values.

Anna Brasile, US Senior Business Development Manager at Qbtech, spearheaded this initiative and shared that “from my past clinical experience with patients from underserved communities and in my current work with non-profit clinics, there has been a lack of resources to implement thorough evaluations and treatment monitoring. QbAccess aims to reduce barriers to care for those who need it most.”

“QbAccess is just the first of what we hope are many initiatives we launch from within our walls. We look forward to awarding our first grant from the program and are excited to hear how we can help applicants in the future,” added Reuterskiöld. “We are proud of all the employees who presented ideas during last year’s Company Days and are thrilled with the conversations, ideas and innovations it has inspired among our team.”

Transforming ADHD care through its technology-first approach, Qbtech’s objective ADHD tests seamlessly integrate into clinical pathways to facilitate a comprehensive diagnosis, as well as more accurately and efficiently determine treatment effects. Available in-clinic and via telehealth, the devices measure motor activity down to the millimeter and aid in evaluating the core symptoms of ADHD – hyperactivity, inattention, and impulsivity – through a 15-20-minute computer-based test. Results are instantly presented in a report that compares a patient's results with an age and sex-at-birth-matched control group without ADHD. The highly visual representation of symptoms, shown as graphs and images on the reports, helps patients see their symptoms clearly, bringing transparency into the diagnostic and treatment management process.

Since its launch in Sweden in 2002, Qbtech has expanded globally. More than 40 independent studies document the company’s benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than self-rating, and standardization of care across multiple disciplines.

Non-profit clinics are encouraged to apply at www.qbtech.com.

About Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241015343013/en/